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Purpose: Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a developmental disease characterized by a
complex eyelid malformation associated or not with premature ovarian failure (POF). BPES is essentially an autosomal
dominant disease, due to mutations in the forkhead box L2 (FOXL2) gene, encoding a forkhead transcription factor. More
than one hundred unique FOXL2 mutations have been described in BPES in different populations, many of which are
missense mutations in the forkhead domain. Here, we report on a very severe form of BPES resulting from a missense
mutation outside the forkhead domain.
Methods: A clinical and molecular genetic investigation was performed in affected and unaffected members of an Iranian
family with BPES. The FOXL2 coding region was sequenced in an index case. Targeted mutation testing was performed
in 8 family members.
Results: We have identified a heterozygous FOXL2 missense mutation c.650C→G (p.Ser217Cys) co-segregating with
disease in members of a three-generation family with BPES type II. Only few missense mutations have been reported
outside the forkhead domain so far. They were all found in mild BPES, in line with in vitro studies demonstrating mostly
normal localization and normal or increased transactivation properties of the mutant proteins. Unlike previous studies,
affected members of the family studied here showed a severe BPES phenotype, with bilateral amblyopia due to uncorrected
ptosis.
Conclusions: This is the first study demonstrating a severe BPES phenotype resulting from a FOXL2 missense mutation
outside the forkhead domain, expanding our knowledge about the phenotypic consequences of missense mutations outside
the forkhead domain in BPES.
Blepharophimosis,  ptosis  and  epicanthus  inversus
syndrome (BPES; OMIM 110100) is a rare genetic condition
basically inherited in an autosomal dominant fashion [1]. The
global prevalence of BPES has been estimated to be ~1 in
50,000 [2]. Two types of BPES have been identified: BPES
type  I  is  a  complex  eyelid  malformation  associated  with
premature ovarian failure (POF), whereas in BPES type II,
only the eyelid defect is present [3]. The major features of the
eyelid malformation involve (1) narrowed horizontal aperture
of the eyelids (blepharophimosis), (2) drooping of the upper
eyelid (ptosis), (3) the presence of a fold of skin arising from
the lower eyelid that runs inward and upward (epicanthus
inversus), and (4) lateral displacement of the inner canthi
(telecanthus) [2,3]. Decock et al. [4] reported that the lateral
displacement of the inferior lacrimal puncta is an important
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anatomic  hallmark  of  BPES,  having  applications  in  the
clinical diagnosis and in the improvement of BPES surgery.
BPES is caused by mutations in the single-exon gene
forkhead box L2 (FOXL2; OMIM 605597) that encodes a
forkhead transcription factor [5,6]. The FOXL2 protein is a
highly conserved protein of 376 amino acids containing a 110-
amino-acid DNA-binding forkhead domain and a polyalanine
tract that is conserved in mammals. The expression pattern of
FOXL2  is  compatible  with  the  BPES  phenotype,  as
expression studies in human, mouse, and goat demonstrated
the presence of the nuclear protein in the mesenchyme of
developing eyelids and in fetal and adult supporting granulosa
cells but not in the oocytes [7]. It is the earliest known marker
of ovarian differentiation in mammals. Moreover, FOXL2 is
strongly expressed in adult follicular cells, suggesting not only
a role in ovarian somatic cell differentiation but also in adult
female fertile life in follicular development and maintenance
[7]. FOXL2 expression has also been demonstrated in the
developing  and  adult  pituitary  [5,8].  In  addition,  a  wider
expression domain is suggested by online resources (Gene
Expression Omnibus; GEO).
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 Sciences, Kerman, IranOf  all  genetic  defects  identified  in  BPES,  intragenic
mutations represent the largest group (81%) [6,9]. Deletions
encompassing FOXL2 and located outside its transcription
unit represent 12% and 5% of molecular defects respectively
[10]. More than 100 unique FOXL2 mutations have been
described  in  BPES.  The  largest  group  (44%)  contains
frameshift  mutations.  Following  are  the  in-frame  changes
(33%, of which polyalanine expansions represent the largest
group),  the  nonsense  mutations  (12%)  and  finally  the
missense  mutations  (11%).  Several  genotype-phenotype
correlations  emerged  after  the  identification  of  the  first
FOXL2 mutations. Initially, it was proposed that mutations
predicted  to  result  in  proteins  with  truncation  before  the
polyalanine  tract  might  by  associated  with  BPES  type  I,
whereas polyalanine expansions might rather lead to BPES
type II. For missense mutations and mutations leading to a
truncated or extended protein containing an intact forkhead
domain and polyalanine tract, no correlations could be made
[6,11]. Functional studies investigating the consequences of
FOXL2 missense mutations have shed light on the molecular
pathogenesis  of  BPES,  and  contributed  to  genotype-
phenotype  correlations  [12-15].  From  the  first  mutation
studies it was hypothesized that these mutations were loss-of-
function alleles leading to haploinsufficiency of FOXL2 [5,
6].  This  was  supported  by  the  observation  that  FOXL2
deletions and intragenic mutations lead to the same phenotype
[6]. This was not clear for missense mutations however.
In this study, we investigated the clinical presentation and
molecular genetic basis of BPES in a three-generation family
from Iranian origin. We demonstrated a severe phenotypic
effect of a FOXL2 missense mutation outside the forkhead
domain.
METHODS
Patients: Recruitment of the family was based on interviews,
questionnaires,  and  clinical  examination  of  affected  and
unaffected individuals by ophthalmologists and geneticists.
An informed consent was obtained in compliance with the
Helsinki Declaration. The pedigree of the family is shown in
Figure 1. Best corrected visual acuity (BCVA) was measured
in all patients by the Early Treatment Diabetic Retinopathy
Study (ETDRS) chart.
Mutation screening: Leukocyte genomic DNA was extracted
from peripheral venous blood from nine subjects by use of
standard methods. Amplification and subsequent sequencing
of  the  entire  coding  region  of  FOXL2  was  performed  as
described in the index case [6]. Briefly, four primer sets were
designed for the coding region of FOXL2 (Table 1). PCR was
conducted in 25 µl reactions containing 100 ng DNA, 10×
PCRx Amplification Buffer (Invitrogen, Carlsbad, CA), 10×
PCRx Enhancer Solution,  0.25 mmol/l of each dNTP, 25
Figure 1. Pedigree of the BPES type II family. Affected individuals are indicated with filled symbols. Abbreviations: wt: wild type allele;
mut: mutant allele.
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212mmol/l  MgSO4,  1  unit  PlatinumTaq  DNA  polymerase
(Invitrogen)  and  50  µmol/l  of  each  oligodeoxynucleotide
primer (IDT, Coralville, IA). Cycling conditions included one
cycle of 94 °C for 4 min followed by 35 cycles of 94 °C for
20 s, 56 °C for 20 s, and 72 °C for 40 s, and one cycle of 72
°C for 10 min. Sequencing was performed with the BigDye
Terminator v3.1 Cycle Sequencing Kit on a ABI 3730XL
genetic  Analyzer,  according  to  the  manufacturer’s
instructions  (Applied  Biosystems,  Carlsbad,  CA).
Segregation analysis was performed in eight affected and
unaffected family members. Mutation nomenclature is based
on GenBank entry AF301906.1, with +1 corresponding to the
A  of  the  translation  initiation  codon  ATG  in  the  cDNA
nomenclature, according to the Human Genome Variation
Society (HGVS) nomenclature guidelines.
Screening  of  the  untranslated  regions  (UTRs):  To  detect
regulatory mutations, sequencing of the 5′ and 3′ untranslated
region (UTR) of FOXL2 was performed in the index patient
and three affected family members. One and five primer sets
were designed for the 5’ UTR and 3’ UTR, respectively (Table
1). PCR for primer set 1 and 2 from the 3’ UTR was conducted
in 30 μl reactions containing 100 ng DNA, 10× PCR Buffer
(Invitrogen), 0.25 mmol/l of each dNTP, 50 mmol/l MgCl2, 1
unit PlatinumTaq DNA polymerase (Invitrogen) and 50 µmol/
l  of  each  oligodeoxynucleotide  primer  (IDT).  Cycling
conditions included one cycle of 94 °C for 4 min followed by
35 cycles of 94 °C for 20 s, 55 °C for 20 s, and 72 °C for 40
s, and one cycle of 72 °C for 10 min. For the other primer sets,
PCR was conducted in 30 μl reactions containing 100 ng
DNA,  10×  PCRx  Amplification  Buffer  (Invitrogen),  10×
PCRx Enhancer Solution, 0.25 mmol/l of each dNTP, 50
mmol/l  MgSO4,  1  unit  PlatinumTaq  DNA  polymerase
(Invitrogen)  and  50  µmol/l  of  each  oligodeoxynucleotide
primer (IDT). Touchdown cycling conditions included one
cycle of 94 °C for 5 min followed by 10 cycles of 94 °C for
30 s, 65 °C (decreasing 1 °C in every cycle) for 15 s, and 72
°C for 60 s followed by 35 cycles of 94 °C for 45 s, 55 °C for
45 s, and 72 °C for 90 s and one cycle of 72 °C for 10 min.
The  UTRs  of  FOXL2,  were  examined  by  direct  Sanger
sequencing of PCR products on an ABI 3730XL Genetic
Analyzer,  according  to  the  manufacturer’s  instructions
(Applied Biosystems).
Quantitative PCR (qPCR) in the FOXL2 region: To detect
copy number variations in the FOXL2 region, quantitative
PCR (qPCR) of the shortest region of overlap (SRO) was
performed as described [16]. In short, 3 qPCR amplicons
located in the SRO were analyzed for the presence of copy
number variants in two affected family members. qPCR was
performed  using  the  qPCR  core  kit  for  SYBR  Green  I
(Eurogentec,  Serzing,  Belgium)  on  the  LightCycler  480
Instrument II (Roche Applied Science, Penzberg, Germany).
Data-analysis was performed with the commercially available
qBasePlus software [17]. Two reference genes were used for
normalization  of  the  relative  quantities  and  two  positives
controls with known copy number were used as a reference to
calculate the copy numbers [18].
RESULTS
Clinical evaluation: We identified a three-generation Iranian
family with multiple members having BPES. The 60 years old
female  proband  (I-2)  was  the  first  member  known  to  be
affected  by  BPES.  She  was  born  at  term  to  non-
consanguineous  healthy  parents  after  an  uneventful
pregnancy. Her other five siblings were normal. Six affected
members in this family span three generations.
The proband presented with severe BPES (Figure 2A).
She  did  not  undergo  any  oculoplastic  surgery.  An
ophthalmologic  exam  revealed  that  she  had  high  myopia,
bilateral amblyopia, and best corrected visual acuity (BCVA)
of  20/100  in  both  eyes  (cyclorefraction:  OD:  −11.25–
3.00x77°;  OS:  −10.00–2.75x85°).  Slit  lamp  evaluation
revealed a normal anterior segment apart from mild nuclear
sclerosis. Fundoscopy demonstrated high myopic changes.
TABLE 1. PCR PRIMERS AND CONDITIONS.
Set Forward sequence (5’→3’)
Melting
temperature (°C) Reverse sequence (5’→3’)
Melting
temperature (°C)
PCR
product
size (bp)
FOXL2 primers
1 ctaggggaaggggaaggag 60.0 gttgtggcggatgctatttt 60.0 500
2 cgaagttcccgttctacgag 59.9 gcatagggcatgggtgag 60.0 391
3 gacggctacggctacctg 59.4 ccaggccattgtacgagttc 60.5 283
4 ccggcgtagtgaactcgta 59.9 aaagcgaaaaagcacagagg 59.6 486
5’ UTR primer
1 ctccttgactgtgcgac 53.1 aaagtgacttggagatgaact 53.0 594
3’ UTR primers
1 gagcgacagaaataaagaagtcc 58.6 ttcaaacctcctgcttctcc 59.4 271
2 cgggtttcacatttctcctt 59.0 ggaagtattgtggccttgga 59.9 366
3 gattttcatatttggatttagcaaac 58.6 gccggacaggactgatgg 62.7 400
4 cggagcaaacacacgtattg 60.2 agggtccctctgtgcttttt 60.1 390
5 gagcgacaggagcttaggaa 59.7 gccatgatgcattgctctta 59.8 247
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213Her son (II-5), 34 years old, presented with high myopia
and  significant  cataract  in  both  eyes.  He  had  horizontal
nystagmus due to deep amblyopia of both eyes and right
esotropia.  BCVA  in  his  right  and  left  eyes  was  counting
fingers at 1.5 m and at 2 m respectively. Fundoscopy showed
high myopic changes similar to his mother. He reported an
unsuccessful repair surgery at the age of 18 (Figure 2B).
A  granddaughter  (III-1)  was  6  years  old.  She  had  a
successful eyelid blepharoplasty (VY-plasty) when she was 6
months. BCVA was 20/20 and 20/30 in her right and left eye
respectively  (cyclorefraction:  OD:  +1.50–2.00x100°;  OS:
+1.00–1.25x70°).  She  had  an  otherwise  normal  ocular
examination.
Apart from malformed lop ears in one of the patients (II-5;
Figure 3), no extra-ocular abnormalities were found in the
other  members.  None  of  the  female  probands  had
oligomenorrhea  or  signs  of  ovarian  dysfunction  and
reproductive problems.
Genetic study: Sequencing of the coding exon of FOXL2 in
the proband (I-2) revealed a heterozygous missense mutation
c.650C→G (p.Ser217Cys). Targeted testing of this mutation
showed  presence  of  this  mutation  in  all  affected  family
members tested in a heterozygous state, and absence in the
unaffected members (Figure 1). Mutation p.Ser217Cys is a
known missense mutation previously described in an Indian
pedigree [13] (Table 2). A different missense mutation in the
same residue p.Ser217Phe has been described previously in
two siblings with mild BPES [12] (Table 2). The Ser217
residue  is  located  outside  the  forkhead  domain  and  is
conserved  throughout  evolution  (Figure  4).  Polyphen  and
SIFT predictions suggest an effect on protein function (Table
2). The Grantham distance between the Ser and Cys residue
is  112.  Taken  together,  the  p.Ser217Cys  mutation  can  be
considered as the causal mutation in this family.
Sequencing of the UTRs of FOXL2 in the proband and
three  affected  family  members  did  not  reveal  a  sequence
variant.  Copy  number  analysis  in  two  affected  family
members using qPCR of the SRO containing a long non-
coding RNA and several conserved non-coding sequences
(CNCs) which interact with the FOXL2 promotor [16], did not
reveal copy number variations (data not shown).
DISCUSSION
A heterozygous missense mutation of FOXL2, p.Ser217Cys,
was  found  to  underly  the  phenotype  here.  Unlike  most
missense  mutations,  this  mutation  is  located  outside  the
forkhead  domain  between  the  forkhead  domain  and  the
polyalanine tract. All missense mutations outside the forkhead
domain found in BPES are summarized in Table 2, with their
phenotypic consequences, in silico predictions and in vitro
assays, if any. In this study, affected patients presented with
a severe form of BPES, leading to amblyopia and poor BCVA
in individuals who did not undergo oculoplastic surgery. In
females  no  signs  of  ovarian  dysfunction  were  present,
suggesting occurrence of type II BPES. This mutation was
previously reported by Nallathambi et al. [13] in an Indian
BPES  family,  with  a  mild  eyelid  phenotype.  A  different
mutation affecting the same residue p.Ser217Phe was found
Figure  2.  BPES  features  in  affected
individuals. A severe form of BPES can
be appreciated in proband I-2 (A) and
II-5  (B),  with  amblyopia  due  to
uncorrected, severe ptosis.
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214in a Belgian BPES family, in which a father and two pre-
pubertal  daughters  displayed  a  similarly  very  mild  BPES
phenotype [12]. Apart from the ocular findings, one of the
siblings presented with alopecia areata, and the other one with
growth hormone deficiency [12]. In addition, Kumar et al.
[19] reported on missense mutation p.Tyr215Cys in an Indian
family, in which all affected individuals exhibited mild to
typical BPES with a normal visual acuity and normal ocular
examination  including  mobility.  All  the  patients  except
individual III-2 had chin elevation and telecanthus. Levator
function was decreased in all the patients [19]. From these
previous  studies  was  concluded  that  missense  mutations
outside the forkhead domain might lead to a rather mild BPES
phenotype.  In  comparison  with  these  previous  mild  cases
however, the BPES phenotype of the affected individuals
reported here is very severe. In those members who did not
undergo successful oculoplastic surgery (I-2 and II-5), this led
to bilateral amblyopia and poor BVCA.
Insights into the molecular effects of FOXL2 missense
mutations  contributing  to  genotype-phenotype  correlations
resulted  from  in  vitro  studies.  First,  the  missense  change
p.Ser217Phe  was  shown  to  have  no  effect  on  subcellular
localization  of  the  FOXL2  protein  and  to  increase  its
transactivation  capacity  on  the  DK3  promoter,  suggesting
hypermorphism  [12].  This  might  be  in  agreement  with
previous  observations  in  FOXC1-related  phenotypes,  in
which  haploinsufficiency  of  FOXC1  and  hypermorphism
(due to gene duplications) lead to similar but not identical
anterior segment phenotypes [20]. Reasoning the same way
for FOXL2, this might explain why hypermorphic mutations
such as p.Ser217Phe would give rise to a somewhat different,
mild BPES phenotype. An equally mild BPES phenotype
resulted  from  a  different  mutation  in  the  same  residue
(p.Ser217Cys)  of  which  neither  localization  nor
transactivation was impaired [12,14]. As said, we identified
the p.Ser217Cys mutation in a severe form of BPES here. As
this severe ocular phenotype was observed in all affected
individuals of different generations, this might be attributed
for instance to a cis-effect of regulatory variants within or
outside the transcription unit modulating the expression of
mutant  FOXL2.  Notably,  as  the  origins  of  the  families
described by Nallathambi et al. [13] and here are different (i.e.,
Indian versus Iranian, respectively), different haplotypes and
regulatory  contexts  might  be  expected.  As  we  could  not
substantiate this hypothesis so far by means of sequencing of
the  UTRs  and  by  copy  number  screening  of  previously
described  SRO  of  regulatory  deletions  this  remains
speculative. However, several alternative possibilities, such
as  subtle  sequence  changes  in  regulatory  elements,  or
promoter variations cannot be ruled out.
In addition, the phenotypic effect seems to be tissue-
specific, as no ovarian involvement was observed in any of
the affected females here. Indeed, this is in line with the study
by Dipietromaria et al. [14], in which a classification tool was
developed  for  FOXL2  intragenic  (missense  and  other)
mutations, correlating the transcriptional activity of FOXL2
mutations on two different reporter promoters and the BPES
type  [14].  Following  this  classification  system,  both
p.Ser217Cys and p.Ser217Phe can be categorized as type II
BPES mutations.
In conclusion, this study has expanded our knowledge
about the phenotypic consequences of missense mutations
outside the forkhead domain of FOXL2 by the identification
Figure 3. Example of abnormal lop ear
(left side) in proband II-5.
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of p.Ser217Cys, for the first time, in a very severe form of
BPES in a family of Iranian descent.T
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